Aronne has consulted for Lilly and was an investigator on the orforglipron clinical trial, and is an advisory board member of both Lilly and Novo
The trial, to be conducted from May 2025, is a 12-week double-blind, randomised, placebo-controlled study involving 100 individuals
When administered to a patient, FA-SNCD@SBA-15/ENZ can selectively bind to cancer cells and deliver drugs directly to them through the mesoporous channels of SBA-15
We provided an intention-to-treat analysis, where we compared the effect of being assigned to the treatment strategies at baseline, regardless of whether or not the individuals continued to follow the strategies during follow-up
People may notice appetite decreases in the first week, but meaningful weight loss appears after weeks
This is especially true in the context of humoral regulation